Phase 2 oncology drug developer Starton Holdings decreases shares offered by 25% ahead of $30 million IPO
Starton Holdings, a Phase 2 developer of controlled release formulations for an approved cancer drug, lowered the proposed deal size for its upcoming IPO on Tuesday. The Paramus, NJ-based company now plans to raise $30 million by offering 5 million shares at a ...read more




